MCID: SCH012
MIFTS: 50

Schizoaffective Disorder

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Schizoaffective Disorder

MalaCards integrated aliases for Schizoaffective Disorder:

Name: Schizoaffective Disorder 12 75 25 55 15 17 72
Schizophreniform Psychosis, Affective Type 25
Schizophrenia, Schizo-Affective Type 25
Schizo-Affective Type Schizophrenia 25
Schizoaffective Schizophrenia 25
Schizo-Affective Psychosis 25
Schizoaffective Psychosis 25

Classifications:



External Ids:

Disease Ontology 12 DOID:5418
ICD9CM 35 295.7
MeSH 44 D011618
NCIt 50 C94378
SNOMED-CT 68 68890003
ICD10 33 F25 F25.9
UMLS 72 C0036337

Summaries for Schizoaffective Disorder

Genetics Home Reference : 25 Schizoaffective disorder is a mental health condition that includes features of both schizophrenia and a mood disorder such as bipolar disorder or depression. The prefix "schizo-" refers to the psychotic symptoms of schizophrenia that affect a person's thinking, sense of self, and perceptions. The term "-affective" refers to extreme shifts in mood, energy, and behavior. Schizoaffective disorder has a wide range of signs and symptoms that make it challenging to diagnose. Its features overlap significantly with those of schizophrenia and bipolar disorder, and there is debate about whether schizoaffective disorder should be considered a separate diagnosis or a subtype of one of these other conditions. Signs and symptoms of psychosis in people with schizoaffective disorder include false perceptions called hallucinations, such as hearing voices no one else can hear or experiencing visions, smells, or tactile (touch) sensations. Strongly held false beliefs (delusions) are also a characteristic feature. For example, affected individuals may be certain that they are a particular historical figure or that they are being plotted against or controlled by others. There are two major types of schizoaffective disorder, based on which mood disorder is involved: the bipolar type and the depressive type. The bipolar type includes both dramatic "highs," called manic episodes, and "lows," called depressive episodes. The depressive type includes only depressive episodes. Manic episodes are characterized by increased energy and activity, irritability, restlessness, an inability to sleep, and reckless behavior. Depressive episodes are marked by low energy and activity, a feeling of hopelessness, and an inability to perform everyday tasks. The psychosis and mood problems associated with schizoaffective disorder usually become evident in adolescence or young adulthood. People with this condition often have difficulty functioning at school, at work, and in social settings. Disordered thinking and concentration, inappropriate emotional responses, erratic speech and behavior, and difficulty with personal hygiene and everyday tasks are also common. People with schizoaffective disorder have a higher risk of substance abuse problems and dying by suicide than the general population.

MalaCards based summary : Schizoaffective Disorder, also known as schizophreniform psychosis, affective type, is related to schizophrenia 2 and depression. An important gene associated with Schizoaffective Disorder is DISC2 (Disrupted In Schizophrenia 2), and among its related pathways/superpathways are Neuroscience and Serotonergic synapse. The drugs Citalopram and Lithium carbonate have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A psychotic disorder that is characterized by recurring episodes of mood fluctuations and a loss of contact with reality.

Wikipedia : 75 Schizoaffective disorder (SZA, SZD or SAD) is a mental disorder characterized by abnormal thought... more...

Related Diseases for Schizoaffective Disorder

Diseases related to Schizoaffective Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 184)
# Related Disease Score Top Affiliating Genes
1 schizophrenia 2 32.2 DRD3 DISC2 DISC1
2 depression 31.4 SLC6A4 HTR2A DISC2 BDNF
3 schizophreniform disorder 31.1 PRL DRD2 COMT
4 tardive dyskinesia 30.9 HTR2A DRD3 DRD2 COMT
5 endogenous depression 30.8 SLC6A4 HTR2A BDNF
6 galactorrhea 30.8 PRL DRD2
7 mental depression 30.7 SLC6A4 HTR2A COMT BDNF
8 hyperprolinemia 30.6 PRODH COMT
9 delusional disorder 30.6 DRD3 DRD2
10 anxiety 30.3 SLC6A4 HTR2A COMT BDNF
11 panic disorder 30.3 SLC6A4 HTR2A COMT
12 paranoid schizophrenia 30.3 SLC6A4 HTR2A COMT BDNF
13 social phobia 30.2 SLC6A4 PRL DRD2
14 opiate dependence 30.2 SLC6A4 DRD3 DRD2
15 tobacco addiction 30.2 SLC6A4 HTR2A DRD2 COMT
16 cocaine dependence 30.2 SLC6A4 DRD3 DRD2
17 cocaine abuse 30.2 SLC6A4 PRL DRD2
18 borderline personality disorder 30.2 SLC6A4 HTR2A COMT BDNF
19 conduct disorder 30.1 SLC6A4 DRD2 COMT
20 early-onset schizophrenia 30.1 HTR2A DRD2 BDNF
21 bipolar i disorder 30.0 SLC6A4 HTR2A DTNBP1 COMT BDNF
22 schizotypal personality disorder 30.0 SULT4A1 COMT
23 substance abuse 30.0 SLC6A4 PRL DRD3 DRD2 COMT BDNF
24 pathological gambling 29.9 SLC6A4 HTR2A DRD3 DRD2
25 personality disorder 29.8 SLC6A4 PRL HTR2A DRD2 COMT BDNF
26 substance dependence 29.8 SLC6A4 DRD3 DRD2 BDNF
27 alcohol dependence 29.5 SLC6A4 HTR2A DRD3 DRD2 COMT BDNF
28 anorexia nervosa 29.4 SLC6A4 PRL HTR2A COMT BDNF
29 obsessive-compulsive disorder 29.1 SLC6A4 SLC1A1 PRL HTR2A DRD3 DRD2
30 autism spectrum disorder 29.0 SLC6A4 HTR2A DISC2 BDNF
31 migraine with or without aura 1 28.9 SLC6A4 NOTCH4 HTR2A DRD3 DRD2 COMT
32 mood disorder 28.5 SLC6A4 HTR2A DRD3 DRD2 DISC2 DISC1
33 major depressive disorder 28.2 SLC6A4 PRL HTR2A DRD3 DRD2 DISC2
34 bipolar disorder 27.8 SLC6A4 PRODH HTR2A DTNBP1 DRD3 DRD2
35 psychotic disorder 27.6 SLC6A4 SLC1A1 RBM12 PRODH PRL HTR2A
36 schizophrenia 25.8 SULT4A1 SLC6A4 SLC1A1 RBM12 PRODH PRL
37 schizophrenia 18 11.5
38 schizophrenia 9 11.5
39 schizophrenia 19 11.5
40 schizophrenia 4 11.1
41 schizophrenia 15 11.1
42 chromosome 2p16.3 deletion syndrome 11.1
43 major affective disorder 8 10.9
44 major affective disorder 9 10.9
45 prolactin producing pituitary tumor 10.4 PRL DRD2
46 substance-induced psychosis 10.4 HTR2A DRD2
47 impulse control disorder 10.4 DRD3 DRD2
48 polysubstance abuse 10.4 DRD3 DRD2 COMT
49 atypical depressive disorder 10.4 SLC6A4 HTR2A
50 alcohol-induced mental disorder 10.4 SLC6A4 DRD2

Graphical network of the top 20 diseases related to Schizoaffective Disorder:



Diseases related to Schizoaffective Disorder

Symptoms & Phenotypes for Schizoaffective Disorder

MGI Mouse Phenotypes related to Schizoaffective Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.93 BDNF COMT DISC1 DRD2 DRD3 DTNBP1
2 homeostasis/metabolism MP:0005376 9.73 BDNF COMT DISC1 DRD2 DRD3 DTNBP1
3 nervous system MP:0003631 9.44 BDNF COMT DISC1 DRD2 DRD3 DTNBP1

Drugs & Therapeutics for Schizoaffective Disorder

Drugs for Schizoaffective Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 322)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Citalopram Approved Phase 4 59729-33-8 2771
2
Lithium carbonate Approved Phase 4 554-13-2
3
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
4
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
5
Ziprasidone Approved Phase 4 146939-27-7 60854
6
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
7
Haloperidol Approved Phase 4 52-86-8 3559
8
Asenapine Approved Phase 4 65576-45-6, 85650-56-2 3001386
9
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
10
Perphenazine Approved Phase 4 58-39-9 4748
11
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
12
Pravastatin Approved Phase 4 81093-37-0 54687
13
Molindone Approved Phase 4 7416-34-4 23897
14
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
15
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
16
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
17
Ondansetron Approved Phase 4 99614-02-5 4595
18
Zinc Approved, Investigational Phase 4 7440-66-6 32051
19
Amisulpride Approved, Investigational Phase 4 53583-79-2, 71675-85-9 2159
20
Fluphenazine Approved Phase 4 69-23-8 3372
21
Fluspirilene Approved, Investigational Phase 4 1841-19-6 3396
22
Sulpiride Approved, Investigational Phase 4 15676-16-1 5355
23
Pimozide Approved Phase 4 2062-78-4 16362
24 Perazine Approved, Investigational Phase 4 84-97-9
25 Benperidol Approved, Investigational Phase 4 2062-84-2
26 bromperidol Approved, Investigational Phase 4 10457-90-6 2448
27
Norepinephrine Approved Phase 4 51-41-2 439260
28
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
29
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
30
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
31
Histamine Approved, Investigational Phase 4 51-45-6 774
32 Coconut Approved Phase 4
33
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
34
Cocaine Approved, Illicit Phase 4 50-36-2 446220 5760
35
Brexpiprazole Approved, Investigational Phase 4 913611-97-9 11978813
36
Racepinephrine Approved Phase 4 329-65-7 838
37
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
38
Acetaminophen Approved Phase 4 103-90-2 1983
39
Losartan Approved Phase 4 114798-26-4 3961
40
Sulfamethazine Approved, Investigational, Vet_approved Phase 4 57-68-1 5327
41
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
42
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
43
Lorazepam Approved Phase 4 846-49-1 3958
44
gamma-Aminobutyric acid Approved, Investigational Phase 4 56-12-2 119
45
Ethanol Approved Phase 4 64-17-5 702
46
Clozapine Approved Phase 4 5786-21-0 2818
47
Amantadine Approved Phase 4 768-94-5 2130
48
Galantamine Approved Phase 4 357-70-0 9651
49
Iloperidone Approved Phase 4 133454-47-4 71360
50
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821

Interventional clinical trials:

(show top 50) (show all 510)
# Name Status NCT ID Phase Drugs
1 Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study Unknown status NCT00708396 Phase 4 Escitalopram
2 Identifying Predictors of Response in 12 Weeks of Treatment With Antipsychotics Using a Treatment Algorithm for Schizophrenia Unknown status NCT01016145 Phase 4 Antipsychotics;Antipsychotics
3 A Study on the Efficacy, Pharmacokinetics and Adverse Effects of Paliperidone ER Unknown status NCT02433717 Phase 4 Paliperidone ER
4 A Multi-Center,Open-Labeled,Intervention Study:The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation Unknown status NCT02935998 Phase 4 Ziprasidone
5 Open Label Prophylaxis Study of Lithium Plus Extended- Release Carbamazepine (Equetro®) Combination for Rapid Cycling Bipolar Disorder Unknown status NCT00325286 Phase 4 Lithium Plus Extended- Release Carbamazepine
6 The Monitor of Serum Prolactin Level and Related Clinical Observations Among Individuals With Schizophrenia Spectrum Illnesses in a 3 Months Aripiprazole Trial Unknown status NCT00468533 Phase 4 Aripiprazole
7 Association of the Amisulpride Treatment Response in Patients With Schizophrenia With the Findings of Brain Structural Magnetic Resonance Imaging Unknown status NCT02095938 Phase 4 amisulpride
8 A Multi-Center Study To Examine The Clinical Effects Of Cross Titration Of Antipsychotics With Ziprasidone In Subjects With Schizophrenia Or Schizoaffective Disorder Completed NCT00649064 Phase 4 Ziprasidone
9 Efficacy of High Dose Olanzapine in a Controlled Fixed Dose-Response Trial for the Treatment of Schizophrenia and Schizoaffective Disorder Completed NCT00100776 Phase 4 Olanzapine
10 A Sixteen-Week, Multi-Center, Open-Label Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone In Subjects Diagnosed With Schizophrenia Or Schizoaffective Disorder Completed NCT00406315 Phase 4 ziprasidone
11 Multicenter, Single Group Study of Aripiprazole Efficacy and Safety in the Acute Psychosis Treatment of Schizophrenia, Schizophreniform Disorder and Schizoaffective Disorder. Completed NCT00304655 Phase 4 Aripiprazole
12 A Multi-center, Randomized, Double Blind, Parallel, PhaseⅣ Trial to Evaluate the Efficacy and Safety of A-prexa Compared to Zyprexa in Patients With Schizophrenia, Schizophreniform Disorder and Schizoaffective Disorder Completed NCT02137993 Phase 4 A-prexa;Zyprexa
13 A Multicenter, Open Label, Flexible-dose, Parallel-group Evaluation of the Cataractogenic Potential of Quetiapine Fumarate (Seroquel) and Risperidone (Risperdal) in the Long Term Treatment of Participants With Schizophrenia or Schizoaffective Disorder Completed NCT00206102 Phase 4 quetiapine fumarate;risperidone
14 The Comparison of Efficacy and Safety of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder Completed NCT00090012 Phase 4 Olanzapine;Quetiapine
15 Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)? Completed NCT00306475 Phase 4 divalproex sodium ER;placebo
16 A Controlled Trial of Olanzapine Versus Active Comparator in the Treatment of Schizophrenic and Schizoaffective Subjects With Comorbid Depression Completed NCT00034801 Phase 4 olanzapine;ziprasidone
17 Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia Completed NCT00103571 Phase 4 Olanzapine;Aripiprazole
18 The Effects of Aripiprazole on Patients With "Metabolic Syndrome": An Open-Label Trial Completed NCT00224822 Phase 4 Aripiprazole
19 A Four-Week Double Blind Multicenter Study Comparing The Efficacy And Safety Of Ziprasidone To Aripiprazole In Subjects With Schizophrenia Or Schizoaffective Disorder Needing Inpatient Care Completed NCT00634348 Phase 4 Aripiprazole;Ziprasidone
20 Ziprasidone Intramuscular/Oral In The Treatment Of Acute Exacerbation Of Schizophrenia Or Schizoaffective Disorder: A Six-Week Open Administration Study Completed NCT00650429 Phase 4 Ziprasidone
21 Clozapine-Augmentation With Ziprasidone or Risperidone, a Randomized, Prospective Trial Completed NCT00224315 Phase 4 ziprasidone;risperidone
22 Effect of Addition of Modafinil on the Tolerability and Efficacy for Cognition of Atypical Antipsychotic Drugs in Patients With Schizophrenia or Schizoaffective Disorder Completed NCT00373672 Phase 4 armodafinil (Nuvigil);placebo
23 The Assessment of a Anti-Obesity Agent for the Treatment of Olanzapine-Associated Weight Gain in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder and Bipolar I Disorder Completed NCT00044187 Phase 4 Sibutramine
24 A Comparison of Long-Acting Injectable Medications for Schizophrenia Completed NCT01136772 Phase 4 haloperidol decanoate;paliperidone palmitate
25 Insulin Sensitivity in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine and Risperidone Completed NCT00190749 Phase 4 olanzapine;risperidone
26 A Randomized, Double Blind Study to Evaluate the Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder Completed NCT00061802 Phase 4 risperidone, quetiapine
27 A Multi-Center Study to Examine The Clinical Effects of Cross Titration of Antipsychotics With Ziprasidone in Subjects With Schizophrenia or Schizoaffective Disorder Completed NCT00137020 Phase 4 ziprasidone
28 Study Evaluating Effectiveness of Ziprasidone Using the Overlapped Switching Strategy in Patients With Schizophrenia or Schizoaffective Disorder Completed NCT01198353 Phase 4 Ziprasidone
29 A Randomized, Parallel Group, Double Blind, Placebo Controlled, Clinical Trial of Augmentation With Atomoxetine for the Treatment of Negative Symptoms in Patients With Schizophrenia and Schizoaffective Disorder Completed NCT00222794 Phase 4 Atomoxetine (Strattera)
30 Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety Completed NCT00177008 Phase 4 Aripiprazole
31 An Open-Label Study Changing Generic Clozapine Formulation to FazaClo® (Clozapine, USP) Orally Disintegrating Tablets in Stable Patients With Schizophrenia or Schizoaffective Disorder Completed NCT00501618 Phase 4 Fazaclo
32 A Single-arm Evaluation of the Safety of Paliperidone Extended-Release (ER) in Subjects With Schizophrenia or Schizoaffective Disorder With Hepatic Disease Completed NCT00535145 Phase 4 Treatment as usual (TAU), Paliperidone ER
33 A Double-Blind Placebo-Controlled Study of Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults With Bipolar Disorder, Major Depressive Disorder, Schizophrenia or Schizoaffective Disorder Completed NCT00845507 Phase 4 Exenatide;Placebo
34 The Assessment of a Weight Management Program for Treatment-Emergent Weight Gain in Patients With Schizophrenia, Schizophreniform Disorder, and Schizoaffective Disorder During Olanzapine Therapy Completed NCT00485823 Phase 4 Olanzapine Hydrochloride
35 Treatment Success in Patients Requiring Treatment Change From Olanzapine to Risperidone Long Acting Injectable (TRESOR) Completed NCT00216632 Phase 4 risperidone
36 BMI Evaluation: Placebo and Active Comparator Trial of Olanzapine Zydis Pills Used Sublingually (PLATYPUS) Completed NCT00303602 Phase 4 Sublingual orally disintegrating olanzapine (SODO);Oral olanzapine
37 Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors, Independent Investigator Study Completed NCT00802919 Phase 4 Varenicline;Placebo for varenicline
38 A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial of Adjunctive Treatment With Pravastatin in Partially Remitted Patients With Schizophrenia or Schizoaffective Disorder Completed NCT00177580 Phase 4 Pravastatin
39 Treatment of Schizophrenia and Related Disorders in Children and Adolescents Completed NCT00053703 Phase 4 Risperidone;Olanzapine (enrollment closed in this treatment);Molindone
40 A Comparison of Risperidone and Haloperidol for Prevention of Relapse in Subjects With Schizophrenia and Schizoaffective Disorders Completed NCT00253110 Phase 4 risperidone;haloperidol
41 Clinical Management of Metabolic Problems in Patients With Schizophrenia Completed NCT00423878 Phase 4 Risperidone;Olanzapine;Quetiapine;Aripiprazole
42 Risperidone Long-Acting for Alcohol and Schizophrenia Treatment (R-LAST) Completed NCT00130923 Phase 4 Risperidone Long Acting;oral risperidone
43 Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (METS) - Pilot Study Completed NCT00816907 Phase 4 Metformin;Placebo
44 A Multicenter, Randomized, Double-blind, Placebo-controlled, 16 Week Study of Aripiprazole Used as Dual Therapy in the Treatment of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder Demonstrating an Inadequate Response to Quetiapine or Risperidone Monotherapy. Completed NCT00325689 Phase 4 Quetiapine or Risperidone + Aripiprazole;Quetiapine or Risperidone + placebo
45 High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia Completed NCT01569659 Phase 4 Lurasidone;Lurasidone
46 An Open-Label Randomized Trial Comparing Risperdal Consta With Oral Antipsychotic Care in the Treatment of Early Psychosis Completed NCT00246259 Phase 4 Risperidone long-acting injection (LAI);Oral Antipsychotic
47 A Six-month, Double-blind, Randomized, International, Multicenter Trial to Evaluate the Glucoregulatory Effects of Risperidone and Olanzapine in Subjects With Schizophrenia or Schizoaffective Disorder Completed NCT00236379 Phase 4 Olanzapine;Risperidone
48 The Effect of Switching to Aripiprazole on Indices of Cardiovascular Health in Overweight and Obese Patients With Schizophrenia Completed NCT00222833 Phase 4 Aripiprazole
49 Naltrexone Treatment of Alcohol Abuse in Schizophrenia Completed NCT00145847 Phase 4 Naltrexone or Placebo
50 A Randomized Open-Label, Rater Blinded Assessment of Optimal Treatment Change Strategy to Risperidone for Patients Intolerant of Olanzapine Completed NCT00378183 Phase 4 risperidone

Search NIH Clinical Center for Schizoaffective Disorder

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Paliperidone

Genetic Tests for Schizoaffective Disorder

Anatomical Context for Schizoaffective Disorder

MalaCards organs/tissues related to Schizoaffective Disorder:

41
Brain, Testes, Cortex, Eye, Prefrontal Cortex, Liver, Bone

Publications for Schizoaffective Disorder

Articles related to Schizoaffective Disorder:

(show top 50) (show all 4095)
# Title Authors PMID Year
1
Impact of serotonin receptor 2A gene haplotypes on C-peptide levels in clozapine- and olanzapine-treated patients. 9 38
20521326 2010
2
Melperone, an aytpical antipsychotic drug with clozapine-like effect on plasma prolactin: contrast with typical neuroleptics. 9 38
19551763 2009
3
Molecular differentiation of schizoaffective disorder from schizophrenia using BDNF haplotypes. 9 38
19336781 2009
4
McLean-Harvard International First-Episode Project: two-year stability of DSM-IV diagnoses in 500 first-episode psychotic disorder patients. 9 38
19200422 2009
5
Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine. 9 38
19142110 2009
6
Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole. 9 38
18786813 2008
7
Brain-derived neurotrophic factor polymorphisms and frontal cortex morphology in schizophrenia. 9 38
18628679 2008
8
Does diagnostic classification of early-onset psychosis change over follow-up? 9 38
17665305 2008
9
Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder. 9 38
18320559 2008
10
Genetic variation in COMT and PRODH is associated with brain anatomy in patients with schizophrenia. 9 38
17504246 2008
11
Dysbindin gene variants are associated with bipolar I disorder in a Korean population. 9 38
17433541 2007
12
The child and adolescent first-episode psychosis study (CAFEPS): design and baseline results. 9 38
17267179 2007
13
The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment. 9 38
16478753 2006
14
COMT genotype and manic symptoms in schizophrenia. 9 38
16828262 2006
15
BDNF gene variants and brain morphology in schizophrenia. 9 38
16741916 2006
16
Hyperprolinemia is not associated with childhood onset schizophrenia. 9 38
16389584 2006
17
Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios. 9 38
16380905 2005
18
COMT genetic variation confers risk for psychotic and affective disorders: a case control study. 9 38
16232322 2005
19
Genomewide linkage scan in schizoaffective disorder: significant evidence for linkage at 1q42 close to DISC1, and suggestive evidence at 22q11 and 19p13. 9 38
16203953 2005
20
DISC1 and neurocognitive function in schizophrenia. 9 38
16056147 2005
21
A frameshift mutation in Disrupted in Schizophrenia 1 in an American family with schizophrenia and schizoaffective disorder. 9 38
15940305 2005
22
Hyperprolinemia is a risk factor for schizoaffective disorder. 9 38
15494707 2005
23
Association between dopamine D3 receptor gene polymorphisms and schizophrenia in an isolate population. 9 38
15567076 2005
24
Disrupted in schizophrenia 1 (DISC1): association with schizophrenia, schizoaffective disorder, and bipolar disorder. 9 38
15386212 2004
25
Association of the DTNBP1 locus with schizophrenia in a U.S. population. 9 38
15362017 2004
26
ProtocadherinX/Y, a candidate gene-pair for schizophrenia and schizoaffective disorder: a DHPLC investigation of genomic sequence. 9 38
15274028 2004
27
A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. 9 38
15121646 2004
28
Long-term observational comparison of risperidone and olanzapine in bipolar disorder. 9 38
15328900 2004
29
Clinical phenotypes associated with DISC1, a candidate gene for schizophrenia. 9 38
15184103 2004
30
Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. 9 38
14744169 2004
31
Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. 9 38
12140115 2002
32
NOTCH4 gene polymorphism and susceptibility to schizophrenia and schizoaffective disorder. 9 38
11239712 2001
33
[Levels and molecular heterogeneity of serotonin transporter protein in platelets of patients with different mental diseases: a comparative analysis with the use of monoclonal and polyclonal antibodies]. 9 38
11523428 2001
34
Ziprasidone: comprehensive overview and clinical use of a novel antipsychotic. 9 38
11060712 2000
35
Negative symptoms of familial schizophrenia breed true in unstable (vs. stable) cerebral-ventricle pedigrees. 9 38
9988837 1999
36
A genome-wide search for schizophrenia susceptibility genes. 9 38
9754621 1998
37
Neuroendocrine responsivity to clomipramine challenge test in neuroleptic naive psychotic patients before and after treatment with haloperidol. 9 38
19698552 1997
38
A comparison of cognitive profiles in schizophrenia and other psychiatric disorders. 9 38
8771446 1996
39
Allelic variation in the D4 dopamine receptor (DRD4) gene does not predict response to clozapine. 9 38
7944879 1994
40
Self-other differentiation among psychotic and conduct-disordered adolescents as measured by human figure drawings. 9 38
8483645 1993
41
Exclusion of linkage between schizophrenia and the D2 dopamine receptor gene region of chromosome 11q in 112 Irish multiplex families. 9 38
8439241 1993
42
Prolactin response to low-dose haloperidol challenge in schizophrenic, non-schizophrenic psychotic, and control subjects. 9 38
2255750 1990
43
How Well Does the DSM-5 Capture Schizoaffective Disorder? 38
31181975 2019
44
Neutrophil/lymphocyte ratio: Can a non-specific marker of inflammation helps to confirm the inflammatory hypothesis of the serious mental diseases? A case-control study. 38
31383340 2019
45
The influence of religious activity and polygenic schizophrenia risk on religious delusions in schizophrenia. 38
30611655 2019
46
Divergence of subjective and performance-based cognitive gains following cognitive training in schizophrenia. 38
30660574 2019
47
Initial Seizure Threshold in Brief-Pulse Bilateral Electroconvulsive Therapy in Patients with Schizophrenia or Schizoaffective Disorder. 38
31429220 2019
48
Factors associated with poor satisfaction with treatment and trial discontinuation in chronic schizophrenia. 38
29866212 2019
49
[Bipolar disorder vulnerability: The vitamin D path]. 38
31434497 2019
50
The effects of cognitive remediation in patients with affective psychosis: A systematic review: Special Section on "Translational and Neuroscience Studies in Affective Disorders". Section Editor, Maria Nobile MD, PhD. This Section of JAD focuses on the relevance of translational and neuroscience studies in providing a better understanding of the neural basis of affective disorders. The main aim is to briefly summaries relevant research findings in clinical neuroscience with particular regards to specific innovative topics in mood and anxiety disorders. 38
30878159 2019

Variations for Schizoaffective Disorder

Expression for Schizoaffective Disorder

Search GEO for disease gene expression data for Schizoaffective Disorder.

Pathways for Schizoaffective Disorder

GO Terms for Schizoaffective Disorder

Cellular components related to Schizoaffective Disorder according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 glutamatergic synapse GO:0098978 9.76 HTR2A DTNBP1 DRD3 DRD2
2 dendrite GO:0030425 9.72 HTR2A GABRB1 DRD2 COMT BDNF
3 postsynaptic membrane GO:0045211 9.71 GABRB1 DTNBP1 DISC1 COMT
4 dendritic spine GO:0043197 9.67 DTNBP1 DRD2 COMT
5 GABA-ergic synapse GO:0098982 9.54 GABRB1 DRD3 DRD2
6 dopaminergic synapse GO:0098691 9.43 DRD3 DRD2
7 integral component of presynaptic membrane GO:0099056 9.43 SLC6A4 HTR2A DRD2
8 axon GO:0030424 9.35 HTR2A DTNBP1 DRD2 COMT BDNF
9 integral component of postsynaptic membrane GO:0099055 9.33 SLC6A4 HTR2A DRD2
10 integral component of plasma membrane GO:0005887 9.23 SLC6A4 SLC1A1 PCDH11X NOTCH4 HTR2A GABRB1
11 plasma membrane GO:0005886 10.22 SLC6A4 SLC1A1 PCDH11X NOTCH4 HTR2A GABRB1

Biological processes related to Schizoaffective Disorder according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 response to toxic substance GO:0009636 9.73 SLC6A4 GABRB1 DRD2
2 memory GO:0007613 9.71 SLC6A4 HTR2A BDNF
3 regulation of synaptic vesicle exocytosis GO:2000300 9.65 HTR2A DTNBP1 DRD2
4 arachidonic acid secretion GO:0050482 9.63 DRD3 DRD2
5 positive regulation of neuroblast proliferation GO:0002052 9.62 DRD2 DISC1
6 temperature homeostasis GO:0001659 9.62 HTR2A DRD2
7 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.61 DRD3 DRD2
8 synaptic transmission, dopaminergic GO:0001963 9.61 DRD3 DRD2
9 negative regulation of protein secretion GO:0050709 9.6 DRD3 DRD2
10 dopamine receptor signaling pathway GO:0007212 9.59 DRD3 DRD2
11 response to ethanol GO:0045471 9.58 DRD3 DRD2
12 prepulse inhibition GO:0060134 9.58 DRD3 DRD2
13 positive regulation of renal sodium excretion GO:0035815 9.57 DRD3 DRD2
14 G protein-coupled receptor internalization GO:0002031 9.55 DRD3 DRD2
15 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.51 DRD3 DRD2
16 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.49 HTR2A DRD2
17 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.46 DRD3 DRD2
18 negative regulation of dopamine receptor signaling pathway GO:0060160 9.43 DRD3 DRD2
19 regulation of dopamine secretion GO:0014059 9.43 HTR2A DTNBP1 DRD3
20 response to histamine GO:0034776 9.4 DRD3 DRD2
21 regulation of locomotion involved in locomotory behavior GO:0090325 9.37 DRD3 DRD2
22 behavioral response to cocaine GO:0048148 9.33 HTR2A DRD3 DRD2
23 acid secretion GO:0046717 9.32 DRD3 DRD2
24 ovulation cycle GO:0042698 9.22 GABRB1
25 dopamine metabolic process GO:0042417 9.13 DRD3 DRD2 COMT
26 response to drug GO:0042493 9.02 SLC6A4 HTR2A DRD3 DRD2 COMT

Molecular functions related to Schizoaffective Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 adrenergic receptor activity GO:0004935 9.37 DRD3 DRD2
2 drug binding GO:0008144 9.33 HTR2A DRD3 DRD2
3 dopamine binding GO:0035240 9.32 DRD3 DRD2
4 serotonin binding GO:0051378 9.26 SLC6A4 HTR2A
5 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 8.96 DRD3 DRD2
6 dopamine neurotransmitter receptor activity GO:0004952 8.62 DRD3 DRD2

Sources for Schizoaffective Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....